Virtual consulting · Worldwide
NeuciteConsultingRequest a quote
Pharmaceutical

Technical and compliance support for small and mid-size pharma

Formulation problems, unvalidated methods, quality-system gaps and safety obligations slow small pharma teams down. We prepare the technical work and gap assessments that move them forward, virtually and worldwide.

Virtual
Delivered remotely, in English
Global
Open to teams worldwide
Scoped
Written project quotation
Written
Reports, plans and memos

What we prepare for pharmaceutical teams

Each item links to a service page with deliverables, inputs and boundaries. We prepare technical evidence, plans and strategy. We do not certify products, approve submissions or give legal opinions.

⚗️

Formulation development

Root-cause work on solubility, crystallization and stability, solvent systems for topical products, and stability-study design.

Formulation development
🧪

Analytical methods

Method development plans, validation against ICH Q2(R2), specifications and extractables and leachables study plans.

Assay development
✅

GMP and GxP gap assessment

Gap assessments against GMP, GLP and ISO 13485 expectations, plus data-integrity review of electronic records against ALCOA+.

GMP and GxP compliance
🔎

Inspection readiness

Mock inspections, inspection-room process and staff training, and response plans for inspection observations.

Inspection readiness
⚕️

Pharmacovigilance

Safety system and PSMF design, outsourcing oversight and routine signal screening. We do not serve as your QPPV.

Pharmacovigilance
🔍

Competitive intelligence

Pipeline and trial-registry tracking, technology landscapes and monthly literature digests that a scientist verifies.

Competitive intelligence

Launch and market-access questions are covered under commercialization and regulatory and market access.

Problems we are typically asked to solve

These describe typical client types and problems. They are not client results, and we cannot promise outcomes, approvals or timelines.

01

A topical drug crystallizes in the tube

Specialty pharma company. A topical product forms crystals during storage, and the team is unsure whether the cause is supersaturation, the solvent system or the packaging.

How we advise. We review the composition, solubility data and storage conditions, then propose reformulation options and a stability-study design.

You receive. A root-cause assessment, ranked reformulation options and a stability test plan.

02

First marketing authorization, no safety system

Small drug sponsor. The company is approaching its first marketing authorization and has no pharmacovigilance system, safety database or core procedures.

How we advise. We design the system and PSMF, list the core SOPs, and set vendor selection and oversight criteria.

You receive. A system design, a draft PSMF outline, an SOP list and vendor criteria.

03

The first inspection is coming

Drug manufacturer. Staff have never faced an inspector, and the quality system has not been tested against inspection questions.

How we advise. We run a mock inspection with storyboards, record findings by risk and plan gap closure with your team.

You receive. A risk-ranked findings list, a remediation plan and staff briefing material.

Describe your pharmaceutical project

Send a general description of the problem and your deadline. A scientist follows up by email and prepares a written quote once the scope is clear.